


89 Re PTO 08 NOV 1996

FORM PTO-1390 (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			223/051
INTERNATIONAL APPLICATION NO. PCT/CA95/00287	INTERNATIONAL FILING DATE 12 May 1995	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 08/737446	
TITLE OF INVENTION TREATMENT OF DIABETES		PRIORITY DATE CLAIMED 12 May 1994	
APPLICANT(S) FOR DO/EO/US AMYLIN PHARMACEUTICALS, INC.			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11. to 16. below concern other document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input type="checkbox"/> Other items or information:</p>			

89 Rec 1 PCT/PTO 08 NOV 1996

17. <input checked="" type="checkbox"/> The following fees are enclosed:		910.00		CALCULATIONS		PTO USE ONLY	
Basic National Fee (37 CFR 1.492(a)(1)-(5)):							
Search Report has been prepared by the EPO or JPO.....		\$ 884.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482)		\$ 680.00					
No international preliminary examination fee paid to USPTO (37 CFR 1.482)							
but international search fee paid to USPTO (37 CFR 1.445(a)(2))..		\$ 750.00					
Neither international preliminary examination fee (37 CFR 1.482) nor							
international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....		\$ 1,010.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482)							
and all claims satisfied provisions of PCT Article 33(2)-(4).....		\$ 94.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 910			
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$			
months from the earliest claimed priority date (37 CFR 1.492(e)).							
Claims	Number Filed	Number Extra	Rate				
Total 19 Claims	19 -20 =	0	X \$22.00	\$ 0.00			
Independent Claims	6 -3 =	3	X \$78.00	\$ 240.00			
Multiple dependent claims(s) (if applicable)			+ \$ 250.00	\$ 260.00			
TOTAL OF ABOVE CALCULATIONS =				\$ 1,540.00			
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement				\$			
must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				770.00		-	
SUBTOTAL =				\$ 770.00			
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$			
months from the earliest claimed priority date (37 CFR 1.492(f)).				+			
TOTAL NATIONAL FEE =				\$ 770.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be				\$			
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +							
TOTAL FEES ENCLOSED =				\$ 770.00			
				Amount to be:			
				refunded \$			
				charged \$			
<p>a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>01-0535</u> in the amount of \$ <u>770.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>01-0535</u>. A duplicate copy of this sheet is enclosed.</p>							
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>							
SEND ALL CORRESPONDENCE TO:				SIGNATURE			
Bradford J. Duft							
Lyon & Lyon, LLP				Bradford J. Duft			
633 West 5th Street				NAME			
47th floor				32,219			
Los Angeles, CA 90071				REGISTRATION NUMBER			

Form PTO-1390 (REV 5-93)

(Transmittal Letter to the United States Designated Office(DO/US)—Entry Into National Stage Under 35 USC 371—PTO 1390 [13-7]—page 2 of 2)

958077-9442730

Attorney's Docket No. 223/051**IN THE UNITED STATES**

- ☐ RECEIVING OFFICE (RO/US)
☒ DESIGNATED OFFICE (DO/US)
☐ ELECTED OFFICE (EO/US)

PCT/CA95/00287 12 May 1995 12 May 1994
 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED
TREATMENT OF DIABETES
 TITLE OF INVENTION
AMYLIN PHARMACEUTICALS, INC.
 APPLICANT(S)

Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

VERIFIED CERTIFICATION OF EXPRESS MAILING DATE
(INTERNATIONAL APPLICATION (37 CFR 1.10(c))

I declare that, on November 8, 1996, deposited, with the United States Postal Service, in an envelope "Express Mail, Post Office to Addressee," bearing Label Number **RB921444018 US**, addressed to the "Assistant Commissioner for Patents, Washington, D.C. 20231," and having an express mail certification that I executed, the following papers:

Transmittal Letter, Verified Statement Claiming Small Entity, unexecuted
copy of Combined Declaration and Power of Attorney, PCT/IPEA/416,
PCT Request, PCT/IB/301, PCT/IB/304, PCT/ISA/220, PCT Demand,
Response to Written Opinion, PCT/IPEA/408, and Published
PCT Application; and return reply postcard


A copy of these papers from the file of this application is attached.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

Cynthia McGarvie

(typed or printed name of person making this verified statement)

Date 11/8/96


Signature of person making this verified statement